In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kyprolis Wins Full Monotherapy OK, Broader Combo Use

This article was originally published in Scrip

Executive Summary

The FDA on Jan. 21 granted Amgen Inc. approval to market Kyprolis (carfilzomib) in combination with dexamethasone or with Celgene Inc.'s Revlimid (lenalidomide) plus dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

You may also be interested in...



Myeloma Survival Benefit May Help Amgen's Kyprolis Stave Off Competition

Proving a survival benefit in the head-to-head ENDEAVOR relapsed multiple myeloma study gives Amgen's Kyprolis a leg up ahead of the entry of Velcade generics in the US this year.

Janssen Oncology Strategy: Take A Holistic Approach To R&D

With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Topics

UsernamePublicRestriction

Register

SC064280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel